MX2018014933A - Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis. - Google Patents
Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis.Info
- Publication number
- MX2018014933A MX2018014933A MX2018014933A MX2018014933A MX2018014933A MX 2018014933 A MX2018014933 A MX 2018014933A MX 2018014933 A MX2018014933 A MX 2018014933A MX 2018014933 A MX2018014933 A MX 2018014933A MX 2018014933 A MX2018014933 A MX 2018014933A
- Authority
- MX
- Mexico
- Prior art keywords
- hypercalciuria
- nephrolithiasis
- compositions
- methods
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 206010020590 Hypercalciuria Diseases 0.000 title abstract 2
- 206010029148 Nephrolithiasis Diseases 0.000 title abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000395 magnesium oxide Substances 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 238000011287 therapeutic dose Methods 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 235000019143 vitamin K2 Nutrition 0.000 abstract 1
- 239000011728 vitamin K2 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pediatric Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344653P | 2016-06-02 | 2016-06-02 | |
| PCT/US2017/035514 WO2017210467A1 (en) | 2016-06-02 | 2017-06-01 | Methods and compositions for treatment of hypercalciuria and nephrolithiasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014933A true MX2018014933A (es) | 2019-04-09 |
Family
ID=60479095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014933A MX2018014933A (es) | 2016-06-02 | 2017-06-01 | Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis. |
| MX2022013681A MX2022013681A (es) | 2016-06-02 | 2018-11-30 | Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013681A MX2022013681A (es) | 2016-06-02 | 2018-11-30 | Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200315233A1 (enExample) |
| EP (1) | EP3463322A4 (enExample) |
| JP (2) | JP2019517482A (enExample) |
| AU (1) | AU2017274438A1 (enExample) |
| BR (1) | BR112018075067A2 (enExample) |
| CA (1) | CA3026143A1 (enExample) |
| CO (1) | CO2018013999A2 (enExample) |
| CR (1) | CR20180576A (enExample) |
| DO (1) | DOP2018000265A (enExample) |
| EC (1) | ECSP19000167A (enExample) |
| MX (2) | MX2018014933A (enExample) |
| NI (1) | NI201800126A (enExample) |
| TW (1) | TW201808271A (enExample) |
| WO (1) | WO2017210467A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109806225B (zh) * | 2019-03-16 | 2021-06-01 | 西安安健药业有限公司 | 维生素k1脂肪乳注射液 |
| CN112438967A (zh) * | 2019-08-27 | 2021-03-05 | 高兵 | 维生素k在制备泌尿系结石防治药物和保健品中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4446024C2 (de) * | 1994-12-22 | 1997-01-23 | Bartz Volker | Verwendung eines Vitamins der K-Gruppe |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| CN1322530A (zh) * | 2000-05-09 | 2001-11-21 | 詹炳炎 | 一种防治泌尿系结石的药物——尿石净 |
| EP1411951B2 (en) * | 2001-07-27 | 2010-11-10 | N.V. Nutricia | Enteral compositions for the prevention and/or treatment of sepsis |
| US20050233461A1 (en) * | 2002-06-05 | 2005-10-20 | Douglas Levinson | High-throughput methods and systems for screening of compounds to treat/prevent kidney disorders |
| US8703209B2 (en) * | 2003-06-17 | 2014-04-22 | Edward Larry McCleary | Composition and method for modulating hydrogen ion physiology |
| US20080220094A1 (en) * | 2006-11-01 | 2008-09-11 | Wyeth | Compositions and methods for the treatment and/or prevention of osteoporosis |
| AU2008322224B2 (en) * | 2007-07-24 | 2012-05-10 | Synergia Life Sciences Pvt Limited | Treatments using vitamin K analogues and derivatives |
| JP2013504572A (ja) * | 2009-09-14 | 2013-02-07 | ネステク ソシエテ アノニム | 外因性ビタミンｋ２を含む炎症調節用栄養組成物 |
| US20110229587A1 (en) * | 2009-09-24 | 2011-09-22 | Algaecal Distribution Inc. | Calcium Supplements for the Treatment of Diabetes |
| US20140031432A1 (en) * | 2010-08-06 | 2014-01-30 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| US20150359807A1 (en) * | 2014-06-11 | 2015-12-17 | Supernutrition Life-Extension Research, Inc. | Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof |
-
2017
- 2017-06-01 WO PCT/US2017/035514 patent/WO2017210467A1/en not_active Ceased
- 2017-06-01 CR CR20180576A patent/CR20180576A/es unknown
- 2017-06-01 JP JP2018562172A patent/JP2019517482A/ja active Pending
- 2017-06-01 AU AU2017274438A patent/AU2017274438A1/en not_active Abandoned
- 2017-06-01 US US16/305,040 patent/US20200315233A1/en active Pending
- 2017-06-01 CA CA3026143A patent/CA3026143A1/en active Pending
- 2017-06-01 EP EP17807504.0A patent/EP3463322A4/en not_active Withdrawn
- 2017-06-01 MX MX2018014933A patent/MX2018014933A/es unknown
- 2017-06-01 BR BR112018075067-0A patent/BR112018075067A2/pt not_active IP Right Cessation
- 2017-06-02 TW TW106118261A patent/TW201808271A/zh unknown
-
2018
- 2018-11-30 NI NI201800126A patent/NI201800126A/es unknown
- 2018-11-30 MX MX2022013681A patent/MX2022013681A/es unknown
- 2018-12-03 DO DO2018000265A patent/DOP2018000265A/es unknown
- 2018-12-21 CO CONC2018/0013999A patent/CO2018013999A2/es unknown
-
2019
- 2019-01-02 EC ECSENADI2019167A patent/ECSP19000167A/es unknown
-
2022
- 2022-08-04 JP JP2022124960A patent/JP2022153651A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3026143A1 (en) | 2017-12-07 |
| MX2022013681A (es) | 2022-12-13 |
| WO2017210467A1 (en) | 2017-12-07 |
| CO2018013999A2 (es) | 2019-03-08 |
| ECSP19000167A (es) | 2019-01-31 |
| JP2019517482A (ja) | 2019-06-24 |
| CR20180576A (es) | 2019-04-09 |
| EP3463322A4 (en) | 2019-11-20 |
| TW201808271A (zh) | 2018-03-16 |
| DOP2018000265A (es) | 2019-04-30 |
| JP2022153651A (ja) | 2022-10-12 |
| BR112018075067A2 (pt) | 2019-04-30 |
| US20200315233A1 (en) | 2020-10-08 |
| AU2017274438A1 (en) | 2018-12-13 |
| NI201800126A (es) | 2019-03-28 |
| EP3463322A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811185YA (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| MX2013000319A (es) | Tratamiento de transtornos cognitivos. | |
| WO2018084531A3 (ko) | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| MX2020011737A (es) | Metodos de tratamiento con vitamina d. | |
| EP3318251A3 (en) | Composition for preventing or treating obesity or lipid-related metabolic disease | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2022013681A (es) | Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis. | |
| EP4470625A3 (en) | A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting | |
| WO2018060528A3 (en) | Therapeutic protein | |
| IN2014DN09240A (enExample) | ||
| HK1259026A1 (zh) | 用於治疗癌症的抗趋除剂的局部递送 | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| EP4523759A3 (en) | B-cell depletion as a diagnostic marker | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| PH12020500606A1 (en) | Use of functionalized calcium carbonate as active ingredient | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca | |
| ZA202104321B (en) | Aqueous paediatric retinol formulations | |
| UA118696U (uk) | Спосіб лікування дітей з розладами аутистичного спектру | |
| UA97257U (uk) | Спосіб профілактики та лікування серцево-судинних захворювань | |
| PL3246032T3 (pl) | Kompozycje farmaceutyczne z kwasem zoledronowym, wapniem i witaminą d, odpowiednie do leczenia i/lub profilaktyki chorób metabolicznych kości oraz działań ubocznych spowodowanych terapią, takich jak hipokalcemia | |
| NZ727233A (en) | Stabilized oxymetazoline formulations and their uses |